Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Royal Marsden NHS Foundation Trust, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Istituto Oncologico Veneto, Istituti di Ricovero e Cura a Carattere Scientifico, University of Colorado Cancer Center, University of Colorado Denver, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, The Maria Sklodowska-Curie National Research Institute of Oncology, University of Michigan, Texas Oncology, German Cancer Research Center, Deutschen Konsortium für Translationale Krebsforschung, Swansea University, See-Spital, European Institute of Oncology, Cancer Institute (WIA), Princess Margaret Cancer Centre, Trans Tasman Radiation Oncology Group, Centro de Investigación Biomédica en Red, The Netherlands Cancer Institute, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, KU Leuven, The University of Sydney, Melanoma Institute Australia, Inserm, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Peter MacCallum Cancer Centre, University of California San Diego, Mater Hospital, Odense University Hospital, Bristol-Myers Squibb (United States), Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Cornell University